-
Product Insights
Short Bowel Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Short Bowel Syndrome - Drugs In Development, 2023’, provides an overview of the Short Bowel Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Short Bowel Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Sector Analysis
Short Bowel Syndrome (SBS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Short Bowel Syndrome (SBS) Marketed and Pipeline Drugs Report Overview Short bowel syndrome (SBS) is defined as a condition in which poor absorption of required nutrients from foods occurs due to a lack of sufficient length of the small intestine. SBS usually occurs when portions of the small intestine have been surgically removed due to various underlying conditions like inflammatory bowel disease (IBD), cancer, traumatic injuries, and blood clots in the arteries that supply blood to the intestine. In rare...